<DOC>
	<DOCNO>NCT02695797</DOCNO>
	<brief_summary>The purpose study investigate effect immunotherapy intractable cryptogenic epilepsy patient autoimmune antibody .</brief_summary>
	<brief_title>Immunotherapy Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody</brief_title>
	<detailed_description>Cryptogenic epilepsy epilepsy presume symptomatic nature cause identify . It account least 40 % adult-onset epilepsy . Autoimmune encephalitis include classic paraneoplastic syndrome autoimmune synaptic encephalitis new category immune-mediated disorder often favorable outcome . Recent study report immunotherapy improves seizure outcome medically intractable epilepsy patient clinical serological evidence autoimmune basis . Neural autoantibody detect 22 % epilepsy due unknown cause study , mostly antiepileptic drug ( AED ) -resistant epilepsy group . Of patient receive immunotherapy , 75 % archive &gt; 50 % reduction seizure frequency . Many patient cryptogenic epilepsy refractory AED significant percent cryptogenic epilepsy harbor neural autoantibody . In case , immunotherapy suggestive base favorable outcome immunotherapy autoimmune encephalitis autoimmune epilepsy . Investigators aim investigate response immunotherapy intractable cryptogenic epilepsy patient neural autoantibody .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Autoantibodies</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>A diagnosis cryptogenic epilepsy accord International League Against Epilepsy 's Classification Epilepsy . Intractable epilepsy : Complete seizure control achieve trial two appropriate antiepileptic drug At least 1 seizure within past 8 week Presence autoimmune antibody ( NMDAR , LGI1 , CASPR2 , AMPA1 , AMPA2 , GABABR , antiHu , Yo , Ri , Ma2 , CV2/CRMP5 , amphiphysin , GAD ) serum cerebrospinal fluid Written inform consent sign subject legal guardian prior enter study Clinical evidence autoimmune encephalitis autoimmune limbic encephalitis History severe head trauma Presence structural abnormality think epileptogenic brain MRI Epilepsy predominantly genetic presume genetic origin An active CNS infection , demyelinate disease , degenerative neurologic disease CNS disease deem progressive course study may confound interpretation study result History immunotherapy A history nonepileptic psychogenic seizure within past 1 year Any clinically significant laboratory abnormality opinion Investigator would exclude subject study Any clinically significant psychiatric illness , psychological , behavioral problem , opinion Investigator , would interfere subject 's ability participate study Recent ( within 4 week ) change dose adjustment antiepileptic drug ( 1 2 dos rescue benzodiazepine permit ) Refuse participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Intractable cryptogenic epilepsy autoimmune antibody</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>